<div id="readability-page-1"><h3>Claim 30% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>Bioxcel Therapeutics ( (BTAI) ) has provided an announcement. On March 27, 2026, BioXcel Therapeutics, Inc. entered into a Ninth Amendment to its April 19, 2022 Credit Agreement and Guaranty, under which it agreed to provide additional equity-linked consideration to its lenders. On April 15, 2026, the company issued these lenders warrants to purchase up to 1,353,729 common shares at an exercise price of $0.01 per share, expiring seven years from issuance, signaling further alignment of lender interests with the company’s equity. Also on April 15, 2026, BioXcel executed a Fourth Amended and Restated Registration Rights Agreement with the same lenders to register the common shares issuable upon exercise of the new warrants. The warrants and any underlying shares are being issued under a private placement exemption from Securities Act registration, with the lenders representing investment intent, reflecting a financing structure that may affect future shareholder dilution and capital flexibility. The most recent analyst rating on (BTAI) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Bioxcel Therapeutics stock, see the BTAI Stock Forecast page. Spark’s Take on BTAI Stock According to Spark, TipRanks’ AI Analyst, BTAI is a Neutral. Overall score is held down primarily by very weak financial performance (ongoing losses, cash burn, and negative equity with rising debt) and a bearish technical setup (price below key moving averages with negative MACD). Positive corporate events around IGALMI’s at-home label expansion provide meaningful upside optionality but are not enough to offset the current financial and trend risks. To see Spark’s full report on BTAI stock, click here. More about Bioxcel Therapeutics BioXcel Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics, operating within the life sciences and healthcare sector. The company’s activities commonly involve financing arrangements and equity-linked instruments that support its research, development, and commercialization efforts in its target markets. Average Trading Volume: 1,494,232 Technical Sentiment Signal: Sell Current Market Cap: $28.43M Find detailed analytics on BTAI stock on TipRanks’ Stock Analysis page.</div>

BTAI

LABU

Bioxcel Therapeutics (BTAI) announced a private equity financing deal on April 15, 2026, issuing warrants to lenders for 1,353,729 common shares at $0.01 each, expiring in seven years. This move aligns lender interests with the company's equity and may impact future shareholder dilution. The latest analyst rating for BTAI is a Buy with a $5.00 price target, though Spark's AI Analyst rates it as Neutral due to weak financial performance and bearish technical indicators. Bioxcel focuses on developing therapeutics in the life sciences sector.

Bioxcel Issues Warrants in Private Equity Financing Deal